PureTech Health (PRTC) Share Price, News & Analysis

Company Overview

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: 119 to 123
• 50-Day Range: 118 to 139.20
• 52-Week Range: 104.71 to 146.40
• Volume: 655,961 shs
• Average Volume: 1.08 million shs
• Market Capitalization: £292.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 508
• Consensus Rating: Buy

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:PRTC
• CIK: N/A
• Web: puretechhealth.com
• Phone: +1-617-4822333
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for PureTech Health: GBX 508
• High Price Target: GBX 508
• Low Price Target: GBX 508
• Potential Upside/Downside: +323.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£91.86 million
• Net Margins: -2,355.32%
• Pretax Margin: N/A
• Return on Equity: -31.98%
• Return on Assets: -13.39%

Debt

• Debt-to-Equity Ratio: 6.33
• Current Ratio: 6.59
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: £4.66 million
• Price / Sales: 62.68
• Cash Flow: GBX 56.02 per share
• Price / Cash Flow: 2.14
• Book Value: GBX 113.55 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 243,418,000
• Free Float: N/A
• Market Cap: £292.04 million
• Optionable: Not Optionable
• Beta: 0.79